S
S

Sanofi

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Sanofi targets Dupixent peak sales of over 13 bln euros

PARIS, March 29 (Reuters) - French healthcare group Sanofi SASY.PA , which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion). "This new ambition does not include potential for additional sales ambition upgrade from chronic obst
G
R
S

Healthcare group Sanofi targets Dupixent peak sales of over 13 bln euros

PARIS, March 29 (Reuters) - French healthcare group Sanofi SASY.PA , which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion). "This new ambition does not include potential for additional sales ambition upgrade from chronic obst
G
R
S

UK Stocks-Factors to watch on Feb 24

Feb 24 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Thursday, with futures FFIc1 down 2.04%. * SANOFI-GSK: French drugmaker Sanofi SASY.PA and its British partner GlaxoSmithKline GSK.L are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setba
A
B
B
C
D
D
G
H
I
L
S
S
W
R
U

British Business - Feb 24

Feb 24 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Britain's official climate advisers have left the door open for the government to approve more North Sea oil and gas drilling, saying that the impact on the plane
B
G
S

Financial Times - Feb 24

Feb 24 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Sanofi and GSK to seek approval for delayed COVID-19 vaccine. Link UK should bring forward tax rises to fight inflation, IMF says. Link UK warned future exploration of North Sea risks u
G
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.